Current Treatment of Willis Ekbom Disease
Willis Ekbom Disease (WED) is one of sleep related movements disorders, which is commonly encountered. The treatment of WED has showed many alterations over time. L-dopa is the first dopaminergic agent used to treat to WED, but its use is limited due to adverse effects such as augmentation. Dopamin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2014-09-01
|
| Series: | Türk Uyku Tıbbı Dergisi |
| Subjects: | |
| Online Access: | http://jtsm.org/archives/archive-detail/article-preview/current-treatment-of-willis-ekbom-disease/8956 |
| _version_ | 1828030331708506112 |
|---|---|
| author | Selda Korkmaz Murat Aksu |
| author_facet | Selda Korkmaz Murat Aksu |
| author_sort | Selda Korkmaz |
| collection | DOAJ |
| description | Willis Ekbom Disease (WED) is one of sleep related movements disorders, which is commonly encountered. The treatment of WED has showed many alterations over time. L-dopa is the first dopaminergic agent used to treat to WED, but its use is limited due to adverse effects such as augmentation. Dopamin agonists are the first option in the treatment of WED. These agents are thought to cause less augmentation compared to L-dopa. Of these agents, today, ropinirole, pramipexole and rotigotine have FDA approval. Excessive daytime sleepiness and impulsive control disorders are among important adverse effects. Other agents used to treat WED are α2δ ligands such as gabapentin, gabapentin enacarbil and pregabalin. Of these, only gabapentin enacarbil has FDA approval for the treatment of WED. Although there are several case reports, augmentation has not been demonstrated related to α2δ ligands in long term controlled studies. In secondary WED cases, treatment of associated medical conditions also leads to great improvements in WED symptoms. |
| first_indexed | 2024-04-10T14:27:12Z |
| format | Article |
| id | doaj.art-4aca75fff68644da869ede60def0716c |
| institution | Directory Open Access Journal |
| issn | 2148-1504 |
| language | English |
| last_indexed | 2024-04-10T14:27:12Z |
| publishDate | 2014-09-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Uyku Tıbbı Dergisi |
| spelling | doaj.art-4aca75fff68644da869ede60def0716c2023-02-15T16:09:02ZengGalenos YayineviTürk Uyku Tıbbı Dergisi2148-15042014-09-0113626510.4274/jtsm.014Current Treatment of Willis Ekbom DiseaseSelda Korkmaz0Murat Aksu1Acibadem Üniversitesi Tip Fakültesi, Nöroloji Anabilim Dali, Istanbul, TürkiyeAcibadem Üniversitesi Tip Fakültesi, Nöroloji Anabilim Dali, Istanbul, TürkiyeWillis Ekbom Disease (WED) is one of sleep related movements disorders, which is commonly encountered. The treatment of WED has showed many alterations over time. L-dopa is the first dopaminergic agent used to treat to WED, but its use is limited due to adverse effects such as augmentation. Dopamin agonists are the first option in the treatment of WED. These agents are thought to cause less augmentation compared to L-dopa. Of these agents, today, ropinirole, pramipexole and rotigotine have FDA approval. Excessive daytime sleepiness and impulsive control disorders are among important adverse effects. Other agents used to treat WED are α2δ ligands such as gabapentin, gabapentin enacarbil and pregabalin. Of these, only gabapentin enacarbil has FDA approval for the treatment of WED. Although there are several case reports, augmentation has not been demonstrated related to α2δ ligands in long term controlled studies. In secondary WED cases, treatment of associated medical conditions also leads to great improvements in WED symptoms.http://jtsm.org/archives/archive-detail/article-preview/current-treatment-of-willis-ekbom-disease/8956Willis Ekbom DiseaseL-dopadopamin agonistsa2d ligands |
| spellingShingle | Selda Korkmaz Murat Aksu Current Treatment of Willis Ekbom Disease Türk Uyku Tıbbı Dergisi Willis Ekbom Disease L-dopa dopamin agonists a2d ligands |
| title | Current Treatment of Willis Ekbom Disease |
| title_full | Current Treatment of Willis Ekbom Disease |
| title_fullStr | Current Treatment of Willis Ekbom Disease |
| title_full_unstemmed | Current Treatment of Willis Ekbom Disease |
| title_short | Current Treatment of Willis Ekbom Disease |
| title_sort | current treatment of willis ekbom disease |
| topic | Willis Ekbom Disease L-dopa dopamin agonists a2d ligands |
| url | http://jtsm.org/archives/archive-detail/article-preview/current-treatment-of-willis-ekbom-disease/8956 |
| work_keys_str_mv | AT seldakorkmaz currenttreatmentofwillisekbomdisease AT murataksu currenttreatmentofwillisekbomdisease |